Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea

British Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1996, Pages 191-200

  Lee, T C ^a   Charles, B G ^a   Steer, P A ^b   Flenady, V J ^b   Grant, T C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER MOTHERS HOSPITAL   (Australia)

Author keywords

Apnoea; Bioavailability; NONMEM; Pharmacokinetics; Population; Premature infants; Theophylline

Indexed keywords

THEOPHYLLINE;

APNEA; ARTICLE; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PREMATURE LABOR; PRIORITY JOURNAL; STEADY STATE;

EID: 0029870161     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00182.x     Document Type: Article

References (26)

1. Aranda JV, Turman T. Methylxanthines in apnoea of prematurity. Clin Perinatol 1979; 6: 87-108.
2. Aranda JV, Grondin D, Sasynick BI. Pharmacologic considerations in the therapy of neonatal apnoea. Pediat Clin North Am 1981; 28: 113-133.
3. Collart L, Blaschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992; 18: 71-80.
4. Grasela TH, Sheiner LB. Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 1991; 19 (June suppl.): 25s-36s.
5. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479.
6. Moore EM, Faix RG, Banagale RC, Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinet Biopharm 1989; 17: 47-66.
7. Karlsson MO, Thomson AH, McGovern EM, Chow P, Evans TJ, Kelman AW. Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit 1991; 13: 195-200.
8. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide. University of California, San Francisco, NONMEM Project Group, 1992.
9. Sidhu J, Triggs E, Charles B, Tudehope D, Gray P, Cowley D. Individualizing aminophylline doses in premature infants using bioelectrical impedance: A non-invasive approach. J Pediatr Child Health 1993; 29: 113-118.
10. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 4: 503-512.
11. Loughnan PM, Sitar DS, Ogilvie RI, Eisen A, Fox Z, Neims AH. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediat 1976; 88: 874-879.
12. Bierman CW, Williams PV. Therapeutic monitoring of theophylline: rationale and current status. Clin Pharmacokin 1989; 17: 377-384.
13. Morselli PL, Clinical pharmacokinetics in neonates. Clin Pharmacokin 1976; 1: 81-98.
14. Estelle F, Simons R, Rigatto H, Simons KJ. Pharmacokinetics of theophylline in neonates. Semin Perinatol 1981; 5: 337-345.
15. Driscoll MS, Ludden TM, Casto DT, Littlefield LC. Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. J Pharmacokinet Biopharm 1989; 17: 141-168.
16. Neims AH, Warner M, Loughnan PM, Aranda JV. Developmental aspects of the hepatic cytochrome P450 monooxygenase system. Ann Rev Pharmacol 1976; 16: 427-445.
17. Osborne J, DuMont G, Beecroft M, Ayres AB. Bladder emptying in neonates. Arch Dis Child 1977; 52: 896-898.
18. Sertel H, Scopes J. Rates of creatinine clearance in babies less than one week of age. Arch Dis Child 1973; 48: 717-720.
19. Aranda JV, Sitar DS, Parsons WD, Loughnan PM, Neims AH. Pharmacokinetic aspects of theophylline in premature newborns. N Engl J Med 1976; 295: 413-416.
20. Edwards C. Pharmacokinetics in the neonate. 1. Factors affecting drug disposition. Pharm J 1986; 237: 18-20.
21. The Physiology of the Newborn Infant, eds Smith CA & Nelson NM, Springfield, C.C. Thomas, 1976.
22. Struther A, Throckmorton JK, Herzer C. The influence of high sugar consumption by mice on the duration and action of barbiturates and in vitro metabolism of barbiturates, aniline, and p-nitroanisole. J Pharmacol Exp Ther 1971; 179: 490-498.
23. Hilligoss DM, Jusko WJ, Koup JR, Giacoia G. Factors affecting theophylline pharmacokinetics in premature infants with apnea. Dev Pharmacol Ther 1980; 1: 6-15.
24. Gilman JT, Gal P, Levine RS, Hersh CB, Erkan NV. Factors influencing theophylline disposition in 179 newborns. Ther Drug Monit 1986; 8: 4-10.
25. Dothey CI, Tserng K-Y, Kaw S, King KC. Maturational changes of theophylline pharmacokinetics in preterm infants. Clin Pharmacol Ther 1989; 45: 461-468.
26. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia: Lea & Febiger, 1991: 11-12.